Immutep Ltd reported an EPS of -$0.011 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 4%.

19 Followers

PRRUF Stock Chart & Stats

Advanced Chart >

Day’s Range― - ―

52-Week Range$0.16 - $0.38

Previous CloseN/A

Volume70.00

Average Volume (3M)2.00

Market Cap

$292.88M

Enterprise Value$178.55M

Total Cash (Recent Filing)$12.24M

Total Debt (Recent Filing)$5.78M

Price to Earnings (P/E)―

Beta0.57

Next Earnings

Feb 20, 2025

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding1,455,589,600

10 Day Avg. Volume7

30 Day Avg. Volume2

Standard Deviation0.32

R-Squared0.00024

Alpha0.04

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)209.01

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market Cap0.61

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$0.91

Price Target Upside355.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Immutep Ltd News

PremiumThe Fly

Immutep completes patient enrollment for INSIGHT-003

12d ago

IMMP

PremiumCompany Announcements

Immutep Completes Enrolment for Promising INSIGHT-003 Cancer Trial

13d ago

PremiumThe Fly

Immutep announces initial safety data from Phase I study on IMP761

1M ago

IMMP

PremiumCompany Announcements

Immutep Ltd Announces Cessation of Performance Rights

1M ago

PremiumCompany Announcements

Immutep Reveals Promising Data for IMP761 Trial

1M ago

PremiumThe Fly

Immutep, Monash University announce publication on human LAG-3

1M ago

IMMP

PremiumCompany Announcements

Immutep Ltd Reveals Key LAG-3 Binding Discovery

1M ago

PremiumThe Fly

Immutep announces results from Cohort B of TACTI-003 trial

1M ago

IMMP

See More PRRUF News >

Financials

Annual

Income Statement >

Ownership Overview

1.14% Insiders

0.02% Mutual Funds

― Other Institutional Investors

98.67% Public Companies and

Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Detailed Risk Analysis >

PRRUF FAQ

What was Immutep Ltd’s price range in the past 12 months?

Immutep Ltd lowest stock price was $0.16 and its highest was $0.38 in the past 12 months.

What is Immutep Ltd’s market cap?

Immutep Ltd’s market cap is $292.88M.

When is Immutep Ltd’s upcoming earnings report date?

Immutep Ltd’s upcoming earnings report date is Feb 20, 2025 which is in 32 days.

How were Immutep Ltd’s earnings last quarter?

Immutep Ltd released its earnings results on Aug 28, 2024. The company reported -$0.011 earnings per share for the quarter, beating the consensus estimate of -$0.012 by <$0.001.

Is Immutep Ltd overvalued?

According to Wall Street analysts Immutep Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immutep Ltd pay dividends?

Immutep Ltd does not currently pay dividends.

What is Immutep Ltd’s EPS estimate?

Immutep Ltd’s EPS estimate is -0.01.

How many shares outstanding does Immutep Ltd have?

Immutep Ltd has 1,455,589,600 shares outstanding.

What happened to Immutep Ltd’s price movement after its last earnings report?

Immutep Ltd reported an EPS of -$0.011 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 4%.

Which hedge fund is a major shareholder of Immutep Ltd?

Currently, no hedge funds are holding shares in PRRUF

---

Immutep Ltd Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-25.75%

Trailing 12-Months

Asset Growth

37.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immutep Ltd

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

---

PRRUF Stock 12 Month Forecast

Average Price Target

$0.91

▲(355.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.23819996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.588144981,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.59</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.21,0.2890923046153846,0.36818460923076923,0.44727691384615387,0.5263692184615385,0.6054615230769231,0.6845538276923077,0.7636461323076923,0.8427384369230769,0.9218307415384616,1.0009230461538463,1.080015350769231,1.1591076553846154,{"y":1.23819996,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.21,0.26384615384615384,0.3176923076923077,0.37153846153846154,0.42538461538461536,0.47923076923076924,0.5330769230769231,0.5869230769230769,0.6407692307692308,0.6946153846153846,0.7484615384615385,0.8023076923076923,0.8561538461538462,{"y":0.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.21,0.23908807546153846,0.2681761509230769,0.29726422638461536,0.3263523018461538,0.3554403773076923,0.38452845276923076,0.4136165282307692,0.4427046036923077,0.47179267915384615,0.5008807546153846,0.5299688300769231,0.5590569055384615,{"y":0.588144981,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.17,"date":1682899200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.2,"date":1685577600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.18,"date":1696118400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1704067200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.24,"date":1711929600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.27,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.2,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.17,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.27,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.18,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.21,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Immutep

―

NWBO

Northwest Biotherapeutics

―

CYCC

Cyclacel Pharmaceuticals

―

PSTV

Plus Therapeutics

―

TGTX

TG Therapeutics

―

Compare PRRUF Stocks >

Best Analysts Covering PRRUF

1 Year

Melissa BensonWilsons

1 Year Success Rate

5/14 ratings generated profit

1 Year Average Return

-3.41%

reiterated a buy rating 4 months ago

Copying Melissa Benson's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -3.41% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Immutep Ltd (PRRUF) Stock Price & Analysis

PRRUF Stock Chart & Stats

Immutep Ltd News

Financials

Ownership Overview

Risk Analysis

PRRUF FAQ

Immutep Ltd Stock Smart Score

Analyst Consensus

Blogger Sentiment

News Sentiment

Technicals

Fundamentals

Company Description

Immutep Ltd

PRRUF Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering PRRUF

Become an Expert with TipRanks Premium